These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30485720)

  • 21. Evaluating the impact of the DREAMS partnership to reduce HIV incidence among adolescent girls and young women in four settings: a study protocol.
    Birdthistle I; Schaffnit SB; Kwaro D; Shahmanesh M; Ziraba A; Kabiru CW; Phillips-Howard P; Chimbindi N; Ondeng'e K; Gourlay A; Cowan FM; Hargreaves JR; Hensen B; Chiyaka T; Glynn JR; Floyd S
    BMC Public Health; 2018 Jul; 18(1):912. PubMed ID: 30045711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mathematical insights in evaluating state dependent effectiveness of HIV prevention interventions.
    Zhao Y; Dimitrov DT; Liu H; Kuang Y
    Bull Math Biol; 2013 Apr; 75(4):649-75. PubMed ID: 23435680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimum resource allocation to reduce HIV incidence across sub-Saharan Africa: a mathematical modelling study.
    McGillen JB; Anderson SJ; Dybul MR; Hallett TB
    Lancet HIV; 2016 Sep; 3(9):e441-e448. PubMed ID: 27562745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modelling in concentrated epidemics: informing epidemic trajectories and assessing prevention approaches.
    Boily MC; Shubber Z
    Curr Opin HIV AIDS; 2014 Mar; 9(2):134-49. PubMed ID: 24468893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changing risk behaviours and the HIV epidemic: a mathematical analysis in the context of treatment as prevention.
    Ramadanovic B; Vasarhelyi K; Nadaf A; Wittenberg RW; Montaner JS; Wood E; Rutherford AR
    PLoS One; 2013; 8(5):e62321. PubMed ID: 23671592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frontloading HIV financing maximizes the achievable impact of HIV prevention.
    Anderson SJ; Ghys PD; Ombam R; Hallett TB
    J Int AIDS Soc; 2018 Mar; 21(3):e25087. PubMed ID: 29498234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surveillance and modelling of HIV, STI, and risk behaviours in concentrated HIV epidemics.
    Mills S; Saidel T; Magnani R; Brown T
    Sex Transm Infect; 2004 Dec; 80 Suppl 2(Suppl 2):ii57-62. PubMed ID: 15572641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High Rates of Pre-exposure Prophylaxis Eligibility and Associated HIV Incidence in a Population With a Generalized HIV Epidemic in Rakai, Uganda.
    Ssempijja V; Nakigozi G; Ssekubugu R; Kagaayi J; Kigozi G; Nalugoda F; Nantume B; Batte J; Kigozi G; Yeh PT; Nakawooya H; Serwadda D; Quinn TC; Gray RH; Wawer MJ; Grabowski KM; Chang LW; Van't Hoog A; Cobelens F; Reynolds SJ
    J Acquir Immune Defic Syndr; 2022 Jul; 90(3):291-299. PubMed ID: 35259129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries.
    Pretorius C; Schnure M; Dent J; Glaubius R; Mahiane G; Hamilton M; Reidy M; Matse S; Njeuhmeli E; Castor D; Kripke K
    J Int AIDS Soc; 2020 Feb; 23(2):e25451. PubMed ID: 32112512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential impact of multiple interventions on HIV incidence in a hyperendemic region in Western Kenya: a modelling study.
    Blaizot S; Maman D; Riche B; Mukui I; Kirubi B; Ecochard R; Etard JF
    BMC Infect Dis; 2016 Apr; 16():189. PubMed ID: 27129591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strengthening HIV surveillance: measurements to track the epidemic in real time.
    Buthelezi UE; Davidson CL; Kharsany AB
    Afr J AIDS Res; 2016 Jul; 15(2):89-98. PubMed ID: 27399039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress in Reversing the HIV Epidemic through Intensified Access to Antiretroviral Therapy: Results from a Nationally Representative Population-Based Survey in Kenya, 2012.
    Kim AA; Mukui I; N'gan'ga L; Katana A; Koros D; Wamicwe J; De Cock KM;
    PLoS One; 2016; 11(3):e0148068. PubMed ID: 26930291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PrEP as a feature in the optimal landscape of combination HIV prevention in sub-Saharan Africa.
    McGillen JB; Anderson SJ; Hallett TB
    J Int AIDS Soc; 2016; 19(7(Suppl 6)):21104. PubMed ID: 27760682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda.
    Koss CA; Havlir DV; Ayieko J; Kwarisiima D; Kabami J; Chamie G; Atukunda M; Mwinike Y; Mwangwa F; Owaraganise A; Peng J; Olilo W; Snyman K; Awuonda B; Clark TD; Black D; Nugent J; Brown LB; Marquez C; Okochi H; Zhang K; Camlin CS; Jain V; Gandhi M; Cohen CR; Bukusi EA; Charlebois ED; Petersen ML; Kamya MR; Balzer LB
    PLoS Med; 2021 Feb; 18(2):e1003492. PubMed ID: 33561143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV treatment scale-up: a critical step to controlling HIV epidemic in a resource-limited country.
    Adeyinka DA; Olakunde BO; Morka M; Oladimeji O; Agogo EA
    Public Health; 2018 Nov; 164():68-71. PubMed ID: 30199742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kenya AIDS Indicator Surveys 2007 and 2012: implications for public health policies for HIV prevention and treatment.
    Maina WK; Kim AA; Rutherford GW; Harper M; K'Oyugi BO; Sharif S; Kichamu G; Muraguri NM; Akhwale W; De Cock KM;
    J Acquir Immune Defic Syndr; 2014 May; 66 Suppl 1(Suppl 1):S130-7. PubMed ID: 24732817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. Ending the HIV Epidemic jurisdictions.
    Sullivan PS; Mouhanna F; Mera R; Pembleton E; Castel AD; Jaggi C; Jones J; Kramer MR; McGuinness P; McCallister S; Siegler AJ
    Ann Epidemiol; 2020 Apr; 44():16-30. PubMed ID: 32088073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The global response to HIV in men who have sex with men.
    Beyrer C; Baral SD; Collins C; Richardson ET; Sullivan PS; Sanchez J; Trapence G; Katabira E; Kazatchkine M; Ryan O; Wirtz AL; Mayer KH
    Lancet; 2016 Jul; 388(10040):198-206. PubMed ID: 27411880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The long-term impact and value of curative therapy for HIV: a modelling analysis.
    Guzauskas GF; Hallett TB
    J Int AIDS Soc; 2023 Sep; 26(9):e26170. PubMed ID: 37749063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies.
    Gomez GB; Borquez A; Case KK; Wheelock A; Vassall A; Hankins C
    PLoS Med; 2013; 10(3):e1001401. PubMed ID: 23554579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.